Pravachol Lipid Reduction Falls Short Of Lipitor In Disease Progression Study
This article was originally published in The Tan Sheet
Executive Summary
A recent clinical trial comparing 80 mg atorvastatin (Pfizer's Lipitor) with 40 mg pravastatin (Bristol-Myers Squibb's Pravachol) found the more intensive lipid-lowering treatment reduced progression of coronary atherosclerosis, while moderate lipid-lowering therapy did not
You may also be interested in...
Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins
Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S
Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins
Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S
Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins
Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S